Cryopyrin-Associated Periodic Syndrome
Also known as: Cryopyrin Associated Periodic Syndrome / Cryopyrin-associated Periodic Syndromes (CAPS) / Cryopyrin-Associated Periodic Syndromes / Cryopyrin associated periodic syndrome (disorder) / Chronic infantile neurological cutaneous and articular syndrome / CINCA syndrome / Chronic infantile neurological, cutaneous and articular syndrome (disorder) / Neonatal-onset multisystemic inflammatory disease / NOMID / Chronic Infantile Neurological, Cutaneous, and Articular Syndrome / Familial Cold Autoinflammatory Syndrome / FCAS / Familial cold urticaria (disorder) / Familial cold urticaria / Muckle-Wells Syndrome / Familial amyloid nephropathy with urticaria AND deafness (disorder)
| Drug | Drug Name | Drug Description |
|---|---|---|
| DB00026 | Anakinra | A recombinant form of human interleukin-1 receptor antagonist used in the treatment of rheumatoid arthritis, neonatal-onset multisystem inflammatory disease and deficiency of interleukin-1 receptor antagonist (DIRA). |
| DB06168 | Canakinumab | An interleukin-1β blocker used to treat Periodic Fever Syndromes such as Cryopyrin-Associated Periodic Syndromes (CAPS) and Familial Mediterranean Fever (FMF), and also to treat active Systemic Juvenile Idiopathic Arthritis (SJIA). |
| DB06372 | Rilonacept | An IL-1 inhibitor used to treat cryopyrin-associated periodic syndrome, a rare hereditary inflammatory disorder. |
| Drug | Drug Name | Target | Type |
|---|---|---|---|
| DB00026 | Anakinra | Interleukin-1 receptor type 1 | target |
| DB06168 | Canakinumab | Interleukin-1 beta | target |
| DB06372 | Rilonacept | Interleukin-1 beta | target |
| DB06372 | Rilonacept | Interleukin-1 alpha | target |
| DB06372 | Rilonacept | Interleukin-1 receptor antagonist protein | target |